Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

被引：0
作者：
Cliff Molife
Katherine B. Winfree
Hollie Bailey
Yulia D’yachkova
Cameron Forshaw
Sangmi Kim
Kaisa-Leena Taipale
Tarun Puri
机构：
[1] Eli Lilly and Company,Value, Evidence, and Outcomes
[2] Lilly Corporate Center,Oncology
[3] Adelphi Real World,Lilly International Medical Affairs Oncology
[4] Statistics,undefined
[5] Eli Lilly and Company,undefined
[6] Global Patient Safety-Pharmacoepidemiology,undefined
[7] Eli Lilly and Company,undefined
[8] Value,undefined
[9] Evidence,undefined
[10] and Outcomes-International,undefined
[11] Eli Lilly and Company,undefined
[12] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Advanced non-small cell lung cancer; Disease Specific Programme™; mutation; Patient-reported outcomes; Point-in-time; Real-world; Survey; Treatment patterns;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3135 / 3168
页数：33
相关论文
共 50 条
  • [21] Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study
    Mountzios, Giannis
    Lampaki, Sofia
    Linardou, Helena
    Georgoulias, Vassilis
    Mavroudis, Dimitrios
    Anevlavis, Stavros
    Charpidou, Andriani
    Lykka, Maria
    Spyratos, Dionysis
    Sarris, Evangelos G.
    Somarakis, Alvertos
    Papista, Christina
    Glentis, Alexandros
    Nikolaou, Aristeidis
    Paparepa, Zoe
    Papageorgiou, Foteini
    Syrigos, Konstantinos N.
    FUTURE ONCOLOGY, 2025, 21 (04) : 447 - 462
  • [22] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Fen Wang
    Feng Jin
    Boran Cheng
    Yue Zhang
    Qing Zhou
    Shubin Wang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1721 - 1735
  • [23] Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer
    Khozin, Sean
    Miksad, Rebecca A.
    Adami, Johan
    Boyd, Mariel
    Brown, Nicholas R.
    Gossai, Anala
    Kaganman, Irene
    Kuk, Deborah
    Rockland, Jillian M.
    Pazdur, Richard
    Torres, Aracelis Z.
    Zhi, Jizu
    Abernethy, Amy P.
    CANCER, 2019, 125 (22) : 4019 - 4032
  • [24] Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer
    Melosky, B.
    Banerji, S.
    Blais, N.
    Chu, Q.
    Juergens, R.
    Leighl, N. B.
    Liu, G.
    Cheema, P.
    CURRENT ONCOLOGY, 2020, 27 (02) : E146 - E155
  • [25] Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer
    Velcheti, V.
    Moore, J.
    Wang, H.
    Zhu, X.
    Samyshkin, Y.
    Ward, T.
    Christensen, A.
    Solem, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S600 - S601
  • [26] Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhong, Qiuxia
    Liu, Zhihua
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4115 - 4128
  • [27] Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
    Wagenius, G.
    Vikstrom, A.
    Berglund, A.
    Salomonsson, S.
    Bencina, G.
    Hu, X.
    Chirovsky, D.
    Brunnstrom, H.
    Ekman, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S380 - S381
  • [28] Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review
    Johal, Sukhvinder
    Hettle, Robert
    Carroll, Joe
    Maguire, Peter
    Wynne, Tammy
    JOURNAL OF THORACIC DISEASE, 2021, 13 (06) : 3692 - +
  • [29] Diagnosis, Treatment Patterns, and Outcomes in Real-World Patients with RET Fusion-Positive Non-small Cell Lung Cancer in China
    Lu, Shun
    Shen, Lan
    Wang, Qiming
    Chen, Haiyang
    Zhao, Yi
    Li, Ying
    Segall, Grace
    Khanal, Manoj
    Zhang, Xue
    Ding, Ding
    Shao, Jingxin
    Pang, Long
    ADVANCES IN THERAPY, 2024, 41 (11) : 4248 - 4265
  • [30] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    Investigational New Drugs, 2020, 38 : 1906 - 1914
12345